Klotho Neurosciences, Inc. (KLTO) 10-Year Financial Performance & Capital Metrics

KLTO • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutKlotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. The company is based in Omaha, Nebraska.Show more

Revenue $0
EBITDA -$6M -817.8%
Net Income -$6M -769.4%
EPS (Diluted) -0.32 -45614.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -700.07% -766.3%
ROIC -242.32% -1048.2%
Debt/Equity 0.23 -91.1%
Interest Coverage -15.54 -87.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 98.2% through buybacks

✗Weaknesses

✗Weak momentum: RS Rating 16 (bottom 16%)
✗Low quality earnings: Net income not backed by cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-168.2%

EPS CAGR

10Y-

5Y-

3Y-

TTM-49.77%

ROCE

10Y Avg-213.55%

5Y Avg-213.55%

3Y Avg-248.72%

Latest-621.96%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0
Revenue Growth %	-	-	-	-
Cost of Goods Sold+	0	0	0	0
COGS % of Revenue	-	-	-	-
Gross Profit+	0	0	0	0
Gross Margin %	-	-	-	-
Gross Profit Growth %	-	-	-	-
Operating Expenses+	1.11M	574.37K	631.32K	5.54M
OpEx % of Revenue	-	-	-	-
Selling, General & Admin	1.11M	574.37K	631.32K	5.54M
SG&A % of Revenue	-	-	-	-
Research & Development	0	0	0	0
R&D % of Revenue	-	-	-	-
Other Operating Expenses	0	0	0	0
Operating Income+	-1.11M	-574.37K	-631.32K	-5.54M
Operating Margin %	-	-	-	-
Operating Income Growth %	-	0.48%	-0.1%	-7.78%
EBITDA+	-1.11M	-574.23K	-631.24K	-5.79M
EBITDA Margin %	-	-	-	-
EBITDA Growth %	-	0.48%	-0.1%	-8.18%
D&A (Non-Cash Add-back)	0	0	0	0
EBIT	-1.11M	-574.23K	-631.24K	-5.79M
Net Interest Income+	0	-24.37K	-76.21K	-356.6K
Interest Income	0	0	0	0
Interest Expense	0	24.37K	76.21K	356.6K
Other Income/Expense	44	-24.22K	-76.14K	-610.14K
Pretax Income+	-1.11M	-598.59K	-707.46K	-6.15M
Pretax Margin %	-	-	-	-
Income Tax+	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%
Net Income+	-1.11M	-598.59K	-707.46K	-6.15M
Net Margin %	-	-	-	-
Net Income Growth %	-	0.46%	-0.18%	-7.69%
Net Income (Continuing)	-1.11M	-598.59K	-707.46K	-6.15M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	-0.00	-0.00	-0.00	-0.32
EPS Growth %	-	-	-	-
EPS (Basic)	-0.00	-0.00	-0.00	-0.32
Diluted Shares Outstanding	1.04B	1.04B	1.04B	19.25M
Basic Shares Outstanding	1.04B	1.04B	1.04B	19.25M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	304.52K	329.54K	6.65K	157.81K
Cash & Short-Term Investments	300.85K	75.87K	2.81K	63.74K
Cash Only	300.85K	75.87K	2.81K	63.74K
Short-Term Investments	0	0	0	0
Accounts Receivable	0	0	0	0
Days Sales Outstanding	-	-	-	-
Inventory	0	0	0	0
Days Inventory Outstanding	-	-	-	-
Other Current Assets	0	250K	0	0
Total Non-Current Assets+	736.98K	2.21M	2.19M	2.3M
Property, Plant & Equipment	0	0	0	0
Fixed Asset Turnover	-	-	-	-
Goodwill	0	0	0	0
Intangible Assets	736.98K	2.21M	2.19M	2.3M
Long-Term Investments	0	0	0	0
Other Non-Current Assets	0	0	0	0
Total Assets+	1.04M	2.54M	2.19M	2.46M
Asset Turnover	-	-	-	-
Asset Growth %	-	1.44%	-0.14%	0.12%
Total Current Liabilities+	15.13K	1.36M	1.62M	1.25M
Accounts Payable	15.13K	8.01K	151.26K	63.69K
Days Payables Outstanding	-	-	-	-
Short-Term Debt	0	1.35M	1.47M	271.75K
Deferred Revenue (Current)	0	0	0	0
Other Current Liabilities	0	0	0	0
Current Ratio	20.12x	0.24x	0.00x	0.13x
Quick Ratio	20.12x	0.24x	0.00x	0.13x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	0	0	0	24.49K
Long-Term Debt	0	0	0	0
Capital Lease Obligations	0	0	0	0
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	0	0	0	24.49K
Total Liabilities	15.13K	1.36M	1.62M	1.27M
Total Debt+	0	1.35M	1.47M	271.75K
Net Debt	-300.85K	1.27M	1.46M	208.01K
Debt / Equity	-	1.14x	2.57x	0.23x
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-	-	-	-
Interest Coverage	-	-23.57x	-8.28x	-15.54x
Total Equity+	1.03M	1.18M	571.72K	1.19M
Equity Growth %	-	0.15%	-0.52%	1.07%
Book Value per Share	0.00	0.00	0.00	0.06
Total Shareholders' Equity	1.03M	1.18M	571.72K	1.19M
Common Stock	104.49K	104.49K	1.51K	2.71K
Retained Earnings	-2.62M	-3.22M	-3.92M	-10.56M
Treasury Stock	0	0	0	0
Accumulated OCI	0	751.4K	0	0
Minority Interest	0	0	0	0

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-284.02K	-599.57K	-446.92K	-2.95M
Operating CF Margin %	-	-	-	-
Operating CF Growth %	-	-1.11%	0.25%	-5.59%
Net Income	-1.11M	-598.59K	-707.46K	-6.15M
Depreciation & Amortization	0	0	0	0
Stock-Based Compensation	821.15K	1.4K	0	2.65M
Deferred Taxes	0	0	0	0
Other Non-Cash Items	0	0	0	403.71K
Working Capital Changes	3.85K	-2.38K	260.54K	150.57K
Change in Receivables	0	0	0	0
Change in Inventory	0	0	0	0
Change in Payables	-12.9K	-7.12K	104K	-187.57K
Cash from Investing+	0	-125.41K	23.85K	-123.5K
Capital Expenditures	0	-125.41K	-13.89K	-123.5K
CapEx % of Revenue	-	-	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	0	0	37.74K	0
Cash from Financing+	250K	500K	350K	3.13M
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	0	-241.49K	91K	778.94K
Net Change in Cash	-	-	-	-
Free Cash Flow+	-284.02K	-724.98K	-460.8K	-3.07M
FCF Margin %	-	-	-	-
FCF Growth %	-	-1.55%	0.36%	-5.66%
FCF per Share	-0.00	-0.00	-0.00	-0.16
FCF Conversion (FCF/Net Income)	0.26x	1.00x	0.63x	0.48x
Interest Paid	0	19.62K	78.5K	2.46K
Taxes Paid	0	0	0	551.59K

Key Ratios

Metric	2021	2022	2023	2024
Return on Equity (ROE)	-108.05%	-54.28%	-80.81%	-700.07%
Return on Invested Capital (ROIC)	-	-27.12%	-21.11%	-242.32%
Debt / Equity	-	1.14x	2.57x	0.23x
Interest Coverage	-	-23.57x	-8.28x	-15.54x
FCF Conversion	0.26x	1.00x	0.63x	0.48x

Frequently Asked Questions

Growth & Financials

Klotho Neurosciences, Inc. (KLTO) grew revenue by 0.0% over the past year. Growth has been modest.

Klotho Neurosciences, Inc. (KLTO) reported a net loss of $11.3M for fiscal year 2024.

Dividend & Returns

Klotho Neurosciences, Inc. (KLTO) has a return on equity (ROE) of -700.1%. Negative ROE indicates the company is unprofitable.

Klotho Neurosciences, Inc. (KLTO) had negative free cash flow of $5.6M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener